Payment overview · 2025
General Payments
$1,027.99
38 reported records · 8 companies
Healthcare provider profile · identity verified
Mina N Mikhail, MD
Allopathic & Osteopathic Physicians|Internal Medicine · RIVERSIDE, CA · NPI 1336226786
Verified facts
What the public records show
CMS Open Payments records show Mina N Mikhail, MD received $1,027.99 in general payments during 2025 across 38 reported records.
AstraZeneca Pharmaceuticals LP accounted for 33.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $340.47 | 33.1% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $277.32 | 27.0% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $212.25 | 20.6% | 13 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $86.17 | 8.4% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.00 | 3.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.75 | 3.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $26.16 | 2.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.87 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,027.99 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $277.32 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $264.93 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $212.25 | 13 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $182.18 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $106.64 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $86.17 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.75 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.75 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $26.16 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 104 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
104 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 476 | 160 |
| Levothyroxine Sodium | Levothyroxine Sodium | 279 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 259 | 83 |
| Losartan Potassium | Losartan Potassium | 250 | 73 |
| Metformin Hcl | Metformin Hcl | 220 | 65 |
| Lisinopril | Lisinopril | 207 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 199 | 72 |
| Gabapentin | Gabapentin | 181 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 179 | 55 |
| Furosemide | Furosemide | 148 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 135 | 44 |
| Eliquis | Apixaban | 128 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 43 |
| Alendronate Sodium | Alendronate Sodium | 114 | 36 |
| Farxiga | Dapagliflozin Propanediol | 104 | 31 |
| Meloxicam | Meloxicam | 103 | 35 |
| Jardiance | Empagliflozin | 99 | 24 |
| Allopurinol | Allopurinol | 96 | 22 |
| Omeprazole | Omeprazole | 91 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 29 |
| Donepezil Hcl | Donepezil Hcl | 81 | 23 |
| Ezetimibe | Ezetimibe | 80 | 30 |
| Benazepril Hcl | Benazepril Hcl | 78 | 22 |
| Glimepiride | Glimepiride | 78 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 25 |
| Ozempic | Semaglutide | 74 | 13 |
| Azithromycin | Azithromycin | 71 | 60 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 22 |
| Valsartan | Valsartan | 70 | 21 |
| Famotidine | Famotidine | 67 | 28 |
| Carvedilol | Carvedilol | 65 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 57 | 17 |
| Januvia | Sitagliptin Phosphate | 56 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 56 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 43 |
| Potassium Chloride | Potassium Chloride | 53 | 18 |
| Montelukast Sodium | Montelukast Sodium | 51 | 15 |
| Sodium Chloride | 0.9 % Sodium Chloride | 50 | suppressed |
| Simvastatin | Simvastatin | 49 | 12 |
| Ibuprofen | Ibuprofen | 48 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 12 |
| Atenolol | Atenolol | 42 | 12 |
| Prednisone | Prednisone | 41 | 15 |
| Spironolactone | Spironolactone | 40 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 12 |
| Glipizide | Glipizide | 38 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | suppressed |
| Sucralfate | Sucralfate | 34 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | 14 |
| Meclizine Hcl | Meclizine Hcl | 32 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Calcitriol | Calcitriol | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 15 |
| Lidocaine | Lidocaine | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 15 |
| Memantine Hcl | Memantine Hcl | 28 | 12 |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Cefdinir | Cefdinir | 27 | 22 |
| Fluconazole | Fluconazole | 27 | 14 |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | 14 |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | 12 |
| Finasteride | Finasteride | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 14 |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,027.99 · 38 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, LEQVIO, NEXLETOL, OTEZLA, REPATHA, TRELEGY ELLIPTA, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error